Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with an overall 5-year survival rate of 10%. Disease lethality is due to late diagnosis, early metastasis and resistance to therapy, including immunotherapy. PDA creates a robust fibroinflammatory tumor microenvironment that contributes t...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmiechen, Zoe C., Stromnes, Ingunn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876239/
https://www.ncbi.nlm.nih.gov/pubmed/33584701
http://dx.doi.org/10.3389/fimmu.2020.613815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876239/
https://www.ncbi.nlm.nih.gov/pubmed/33584701
http://dx.doi.org/10.3389/fimmu.2020.613815

Ejemplares similares